Immune Control, HBsAg Loss or Flare Requiring Liver Transplant—Diverse Outcomes After Stopping NUC Therapy

Katarina Lund, Miriam Frankal, Anders Eilard, Joakim Bedner Stenbäck, Erik Alestig, Arno Furquim d’Almeida, Staffan Nilsson, Thomas Vanwolleghem, Johan Westin, Johan Ringlander, Gustaf E. Rydell, Magnus Lindh · 2026

Read Immune Control, HBsAg Loss or Flare Requiring Liver Transplant—Diverse Outcomes After Stopping NUC Therapy by Katarina Lund, Miriam Frankal, Anders Eilard, Joakim Bedner Stenbäck, Erik Alestig, Arno Furquim d’Almeida, Staffan Nilsson, Thomas Vanwolleghem, Johan Westin, Johan Ringlander, Gustaf E. Rydell, Magnus Lindh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13611910.txt.

Description

Katarina Lund and co-authors track what happens when hepatitis B patients stop their daily antiviral pills, in a 2026 study. Long term pill therapy rarely clears a key surface marker of the virus. Stopping can wake the immune system and clear it, but it can also spark a flare. The team followed patients who had taken the pills for at least three years.

Of 25 who stopped, five cleared or nearly cleared the marker and seven reached calm immune control. Six had severe flares and had to restart, and one needed a liver transplant. A related viral marker at the stop date flagged the flare group. The authors urge close, fast blood checks after any stop.

Catalog record

CREATORKatarina Lund, Miriam Frankal, Anders Eilard, Joakim Bedner Stenbäck, Erik Alestig, Arno Furquim d’Almeida, Staffan Nilsson, Thomas Vanwolleghem, Johan Westin, Johan Ringlander, Gustaf E. Rydell, Magnus Lindh
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13611910

Browse the full library · About the Tower of Babel